tbuckley/cabot-search huggingface dataset:
Sexual Response Cycle of Human Female. III. The Clitoris: Anatomic and Clinical Considerations
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Massachusetts Department of Public Health
Authors: John C. Ayres
Journal: New England Journal of Medicine (1951)

ALCOHOLISM — A MEDICAL PROBLEM"Intemperance in eating and in drinking is a symptom of the psyche." So it was written in the fifth century B.C. by Hippocrates or one of his pupils. However, this idea made very little headway until the last decade and a half, when there suddenly developed in some medical and lay circles a trend toward recognizing alcoholism as a disease or, more correctly, a medical syndrome. Experimental findings have begun to replace intuition and clinical activities are demonstrating that the medical approach differs from the propositions of "reform societies."In spite of this recent progress . . .
RAILROAD RATES TO THE JUBILEE MEETING.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply to Tine Hajdinjak and Nadja Kokalj-Vokač’s Letter to the Editor re: Re: Mecedes Marín-Aguilera, Lourdes Mengual, María José Ribal et al. Utility of Fluorescence In Situ Hybridization as a Non-invasive Technique in the Diagnosis of Upper Urinary Tract Urothelial Carcinoma. Eur Urol 2007;51:409–15 and Alan M. Nieder, Mark S. Soloway and Harry W. Herr. Should We Abandon the FISH Test? Eur Urol 2007;51:1469–71. Eur Urol 2007;52:287–9
Authors: M. Marín-Aguilera, A. Alcaraz
Journal: European Urology (2007)
Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113).
Authors: Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Hiroshi Katayama, Makoto Ueno, Masafumi Ikeda, Hiroshi Ishii, Takeshi Azuma, Haruo Iguchi, Shoji Nakamori, Nobumasa Mizuno, Naohiro Sata, Kazuya Sugimori, Kensei Yamaguchi, Tetsuya Mine, Keiji Sano, Hiroyuki Maguchi, Kyoko Shimizu, Junji Furuse
Journal: Journal of Clinical Oncology (2014)

TPS4149 Background: Gemcitabine plus cisplatin (GC) therapy is the standard of care for advanced biliary tract cancer (BTC). However, GC is considered to be toxic because of nausea, vomiting, appetite loss and inconvenient due to requiring hydration before and after cisplatin administration. Our previous JCOG0805 trial, a randomized phase II selection design study of gemcitabine plus S-1 combination therapy (GS) vs. S-1, demonstrated superiority of GS over S-1 in terms of 1-year survival with acceptable toxicity profile and showed GS to be a more promising regimen. This phase III study aims to confirm the non-inferiority of GS to GC in terms of overall survival in patients with recurrent or unresectable BTC. Methods: Eligibility criteria include chemotherapy-naïve patients with recurrent or unresectable biliary tract adenocarcinoma (gallbladder, intrahepatic biliary tract, extrahepatic biliary tract, or ampulla of Vater), an Eastern Cooperative Oncology Group performance status of 0–1, and adequate organ function. Eligible patients are randomized into either GC arm or GS arm. In the GS arm, 1000 mg/m2 of gemcitabine is infused on days 1 and 8, and 30 mg/m2 of S-1 is administered orally twice a day from days 1 to 14; the regimen is repeated every 3 weeks. In the GC arm, 1000 mg/m2 of gemcitabine and 25 mg/m2 of cisplatin are infused on days 1 and 8 and repeated every 3 weeks. The primary endpoint is overall survival and the secondary endpoints are progression-free survival, %response rate, %planned dose, adverse events, clinically relevant adverse events defined as any of grade 2 or more fatigue, appetite loss, nausea, vomiting, mucositis, diarrhea, and serious adverse events. The sample size was calculated to be 350 (175 patients per arm), with a one-sided alpha of 5%, a power of >=80%, assumed median survival time of 11.2 months in GC and of 13 months in GS, an non-inferiority margin of 1.155 in terms of hazard ratio, an accrual period of 4 years, and a follow-up period of 1 year. Twenty-eight institutions are participating in this study. The study was activated in May 2013. Clinical trial information: UMIN000010667.
Nimodipine after resuscitation from out-of-hospital ventricular fibrillation. A placebo-controlled, double-blind, randomized trial
Authors: R. O. Roine
Journal: JAMA (1990)

One hundred fifty-five consecutive patients resuscitated after out-of-hospital ventricular fibrillation by a physician-manned advanced life support unit were randomly assigned to receive nimodipine or placebo at a dosage of 10 μg/kg as an intravenous injection immediately after restoration of spontaneous circulation, followed by an infusion of 0.5 μg/kg per minute for 24 hours. No significant difference was found in the 1-year survival rate of nimodipine-treated (30 [40%] of 75 patients) and placebo-treated patients (29 [36%] of 80 patients). Recurrent ventricular fibrillation during the treatment occurred in one patient in the nimodipine group compared with 12 patients in the placebo group. In a post hoc analysis of patients with very long delays in advanced life support (more than 10 minutes), the 1-year survival rate was higher with nimodipine (eight [47%] of 17 patients) than with placebo (two [8%] of 26 patients). Nimodipine may be of benefit in patients with delayed resuscitation. (<i>JAMA</i>. 1990;264:3171-3177)
Dyspepsia, H pylori, NSAID, bleeding
Authors: I See&, J Sargentoni', B Davidson3, A Burroughs4, H1f Hodgson, U Cox', S Taylor-Robinson', Gillespie Rjs, M Mahir, Zmen Q6l, F Ozmen, C Johnson
Journal: Gut (1996)

The accurate delineation ofhepatic function in patients with cirrhosis is important for management purposes, including the timing of liver transplantation.In viw phosphorus-31 magnetic resonance spectroscopy (3P MRS) is a non-invasive technique, which can be used to provide direct, l6calised biochemical information on hepatic metabolic processes.A typical 31P MR spectrum contains resonances to phosphomonoesters (PME), phosphodiesters (PDE), inorganic phosphate (Pi) and nucleotide triphosphates, including ATP.We studied changes in hepatic 31P MR spectra in vio in liver transplant candidates and characterised underlying biochemical and ceilular abnormalities using in vitro 31p MRS and electron microscopy in 31 patients with cirrhosis of varying aetiology; 14 with compensated cirrhosis (Pugh's score .7)and 17 with decompensated cirrhosis (Pugh's score >8).Peak area ratios of PME and PDE, relative to ATP were measured from in vivo spectra.In vitro spectra were obtained from liver extracts, freeze-clamped at recipient hepatectomy. Phosphoethanolamine(PE), phosphocholine (PC), glycerophosphorylethanolamine (GPE) and glycerophosphorylcholine (GPC) levels were measured.Electron microscopy of liver tissue was also performed.Elevations in PE/ATP and reductions in PDE/ATP were observed with worsening liver function.In vitro spectra showed elevated PE and PC and reduced GPE and GPC, mirroring the in vivo changes, but no distinction was noted between compensated and decompensated cirrhosis in vitro.On electron microscopy, hepatocyte endoplasmic reticulum was reduced with functional decompensation in parenchymal liver disease, but elevated in biliary cirrhosis.Conclusion: The in vio hepatic 31P MR spectral abnormalities in cirrhosis are largely due to changes in phospholipid metabolism.MRS may prove useful as a non- invasive test of hepatic functional reserve.
Abstract 3164: Combined Antithrombotic Therapy in Atrial Fibrillation. Role of different Antiplatelet Strategies
Authors: Francisco Pérez-Gómez, Ramón Bover, Antonio Salvador, María Paz Maluenda, Susana Asenjo, Rosario Pérez-Saldaña, Angel Igea, Marta Suarez, Dulcenombre Coleto, Cristina Fernández
Journal: Circulation (2008)

The NASPEAF trial showed that combined anticoagulant plus antiplatelet therapy was more effective than anticoagulant alone at reducing vascular events in atrial fibrillation (AF) patients. We planned both to validate this benefit during a longer follow-up of patients included in that trial and to assess the hypothesis that combination of anticoagulation plus different antiplatelets could be differently effective and/or safe in patients from that trial and new ones followed-up for at least one year. Methods: Five hundred and seventy-four AF patients were included. Anticoagulation alone therapy (INR 2.0 –3.0) was used as control group (g) 1 to compare with anticoagulation (1.9 –2.5) plus either trifusal 600 mg/d (g2), trifusal 300 mg/d (g3) or aspirin 100 mg/d (g4). Median follow-up was 50, 32, 50 and 37 months respectively. The primary outcome was a composite of ischemic/haemorrhagic stroke, systemic/coronary ischemic events and cardiovascular death. The incidence of severe bleeding was also collected. Anticoagulation was regularly controlled in dedicated units. Results: Long-term follow-up showed benefit of combined anticoagulant plus trifusal 600 mg/d vs anticoagulant alone (primary outcome 2.86% pt/years in g1 vs 1.36% in g2, P=0.014). Combined therapy using other antiplatelet strategies was less effective or safe due to higher incidence of ischemic events when using trifusal 300 mg/d (2.44% pt/years in g3 vs 0.61% in g2, P=0.031) as well as more severe bleeding events with aspirin 100 mg/d (6.60% pt/years in g4 vs 1.51% in g2, P=0.008). Groups g1, g3 and g4 had similar primary outcome (2.86% pt/years, 2.67% and 2.83% respectively). Mean INR and other anticoagulation parameters were similar in the three combined therapy groups. Non-gastric severe bleeding incidence during combined therapy with trifusal 600 mg/d (0.3% pt/years) was lower than that observed in either anticoagulant alone therapy (2.1%, P=0.012) or combined with aspirin (6.60%, P=0.008). In conclusion, long-term follow-up of the NASPEAF trial confirmed the benefit of combined antithrombotic therapy over anticoagulant alone therapy. Combined therapy with aspirin 100 mg/d instead of trifusal 600 mg/d caused higher incidence of severe bleeding.
Role of Ozone and Granular Activated Carbon in the Removal of Mutagenic Compounds
Authors: Marie Marguerite Bourbigot, Marie Claude Hascoet, Yves Levi, Francoise Erb, Nicole Pommery
Journal: Environmental Health Perspectives (1986)

The identification of certain organic compounds in drinking water has led water treatment specialists to be increasingly concerned about the eventual risks of such pollutants to the health of consumers. Our experiments focused on the role of ozone and granular activated carbon in removing mutagenic compounds and precursors that become toxic after chlorination. We found that if a sufficient dose of ozone is applied, its use does not lead to the creation of mutagenic compounds in drinking water and can even eliminate the initial mutagenicity of the water. The formation of new mutagenic compounds seems to be induced by ozonation that is too weak, although these mutagens can be removed by GAC filtration. Ozone used with activated carbon can be one of the best means for eliminating the compounds contributing to the mutagenicity of water. A combined treatment of ozone and activated carbon also decreases the chlorine consumption of the treated water and consequently reduces the formation of chlorinated organic compounds.
Association News
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sisyphus Unbound
Authors: Lloyd Rucker
Journal: Annals of Internal Medicine (1997)

Ad Libitum15 December 1997Sisyphus UnboundLloyd Rucker, MDLloyd Rucker, MDOrange, CA 92868Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-12-199712150-00004 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The Lily in her shivering handWas as white as her skin was brown.She said, “How do you do this day after day?”And she put the Lily down.She matched the angle of my head;She matched the tilt of my frame.She waited for an answer.Then she softly said my name.She said, “How do you draw time's arrow outAnd set it back in its quiver?How do you leach the mischief outFrom the eyes, and the soul, and the liver?”“I don't know if I can, from ... Author, Article, and Disclosure InformationAffiliations: Orange, CA 92868Corresponding Author: Lloyd Rucker, MD, UCIMC, Route 1, 101 City Drive, Orange, CA 92868. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 December 1997Volume 127, Issue 12Page: 1079KeywordsLiver ePublished: 15 August 2000 Issue Published: 15 December 1997 Copyright & PermissionsCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
The Harvey Lectures. Delivered Under the Auspices of the Harvey Society of New York, 1925-1926. Under the Patronage of the New York Academy of Medicine. Series XXI.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Connective Tissue Diseases and Symptoms Associated with Hashimoto's Thyroiditis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Notes on Books
Journal: BMJ (1933)

behaving in like manner, is a superior being governed only by reason, are really not seeking truth, but trying to keep their ends up, or trying to defend some of their favourite habits and pastimes.Once we admit that animals are but simpler editions of ourselves, it is difficult to combine an easy conscience with the enjoyment of such sports as hunting, or suclh self-indulgences as eating the flesh of our poor relations."This passage is representative of the quality of the author's thought and writing.The book could have no stronger recommendation. CYTOLOGICAL TECHNIQUEIn the handy little book entitled Cytological Technique,5 by J. R. BAKER, the student will find a useful guide to the methods of preserving cells or parts of cells in a " life-like " way.The author reminds the reader that both the cytoplasm and the nucleus of a living cell consist of homogeneous watery fluids, which suffer varying degrees of shrinkage and precipitation inito sponge-like, reticulate
Literary Critics of the Medical Profession
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: Results of a case-control study
Authors: L Serfaty
Journal: Hepatology (1997)

The role of the viral genotype, especially genotype 1b, in the severity of liver injury induced by chronic hepatitis C virus (HCV) infection is unclear, probably because of confounding factors such as the date and mode of contamination. Host genetic or environmental factors such as heterozygous MZ α1-antitrypsin deficiency or alcoholism, could also be potential risk factors for the development of cirrhosis. The aim of this study was to compare the prevalence of genotypes, α1-antitrypsin phenotype, past hepatitis B virus infection, and alcohol consumption in cirrhotic and noncirrhotic patients with chronic hepatitis C. We conducted a case-control study comparing 84 consecutive cirrhotic patients with chronic hepatitis C (cases) with 84 noncirrhotic patients with chronic hepatitis C (controls) selected from a cohort of 464 patients hospitalized during the same period. Controls were paired with cases according to age, sex, risk factors, and date of infection. HCV genotypes were determined using the InnoLiPA technique (Innogenetics, Zwijnaarde, Belgium) and classified according to the method of Simmonds. Patients were divided in three groups according to alcohol consumption: <30 g/d (light), 30 to 80 g/d (moderate), and >80 g/d (heavy). Cirrhotic and noncirrhotic patients were not significantly different in terms of genotype distribution (1a/1b/2a/3a/others/undetermined: 10/48/7/17/0/2 versus 11/43/10/10/5/5), α1-antitrypsin phenotype distribution (MM/MS/MZ: 84%/14%/2% vs. 87%/11%/2%, respectively), and prevalence of antibody to hepatitis B core antigen positivity (29% vs. 23%). Alcohol consumption was significantly different between cases and controls (L/M/H: 58%/27%/16% vs. 76%/15%/9%, respectively; P < .05). Two conclusions regarding patients with chronic hepatitis C virus infection can be drawn from this study: 1) viral genotype, especially 1b, past hepatitis B virus infection, and heterozygous MZ α1-antitrypsin deficiency are not risk factors for cirrhosis; and 2) alcohol consumption, even moderate, is a risk factor for cirrhosis.
"ACTIVATION OF E-PROSTANOID4 AND E-PROSTANOID2 RECEPTORS INHIBITS TNF- RELEASE FROM HUMAN ALVEOLAR MACROPHAGES". M.J. RATCLIFFE, A. WALDING, P.A. SHELTON, A. FLAHERTY AND I.G. DOUGALL. EUR RESPIR J 2007; 29: 986 994.
Authors: A Ratcliffe, P Walding, A Shelton, I Flaherty
Journal: European Respiratory Journal (2007)